China's H1N1 Flu Vaccine Said To Pass Phase I Trials
This article was originally published in PharmAsia News
The Health Ministry in China declared its version of an H1N1 flu vaccine has passed Phase I trials showing it to be safe and efficacious. The vaccine already is being prepared for Phase II trials after the initial round turned up no severe adverse reactions among more than 13,000 volunteers. Health Minister Chen Zhu held a news conference to announce the results and received his second injection of the vaccine. (Click here for more
You may also be interested in...
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.